First Time Loading...

Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557

Watchlist Manager
Jiangsu Kanion Pharmaceutical Co Ltd Logo
Jiangsu Kanion Pharmaceutical Co Ltd
SSE:600557
Watchlist
Price: 19.85 CNY -3.97%
Updated: May 16, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Jiangsu Kanion Pharmaceutical Co Ltd

Wall Street analysts forecast Jiangsu Kanion Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Jiangsu Kanion Pharmaceutical Co Ltd is 25.55 CNY with a low forecast of 23.23 CNY and a high forecast of 29.49 CNY.

Lowest Forecast
Wall Street Target
23.23 CNY
17% Upside
Average Forecast
Wall Street Target
25.55 CNY
29% Upside
Highest Forecast
Wall Street Target
29.49 CNY
49% Upside
Lowest
Price Target
23.23 CNY
17% Upside
Average
Price Target
25.55 CNY
29% Upside
Highest
Price Target
29.49 CNY
49% Upside
Jiangsu Kanion Pharmaceutical Co Ltd Competitors:
Price Targets
COLL
Collegium Pharmaceutical Inc
20% Upside
600594
Guizhou Yibai Pharmaceutical Co Ltd
59% Upside
S
002399
Shenzhen Hepalink Pharmaceutical Group Co Ltd
35% Downside
A
506260
Anuh Pharma Ltd
15% Upside
COLL
Collegium Pharmaceutical Inc
20% Upside
600594
Guizhou Yibai Pharmaceutical Co Ltd
59% Upside
S
002399
Shenzhen Hepalink Pharmaceutical Group Co Ltd
35% Downside
A
506260
Anuh Pharma Ltd
15% Upside
DMP
Dermapharm Holding SE
51% Upside
T
300119
Tianjin Ringpu Bio-Technology Co Ltd
32% Upside
688578
Shanghai Allist Pharmaceuticals Co Ltd
36% Downside
SOLARA
Solara Active Pharma Sciences Ltd
16% Downside

Revenue
Forecast

Revenue Estimate
Jiangsu Kanion Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Jiangsu Kanion Pharmaceutical Co Ltd's revenue is 7%. The projected CAGR for the next 3 years is 17%.

7%
Past Growth
17%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Jiangsu Kanion Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Jiangsu Kanion Pharmaceutical Co Ltd's operating income is 2%. The projected CAGR for the next 3 years is 21%.

2%
Past Growth
21%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Jiangsu Kanion Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Jiangsu Kanion Pharmaceutical Co Ltd's net income is 5%. The projected CAGR for the next 3 years is 20%.

5%
Past Growth
20%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Jiangsu Kanion Pharmaceutical Co Ltd's stock price target?
Price Target
25.55 CNY

According to Wall Street analysts, the average 1-year price target for Jiangsu Kanion Pharmaceutical Co Ltd is 25.55 CNY with a low forecast of 23.23 CNY and a high forecast of 29.49 CNY.

What is Jiangsu Kanion Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
17%

For the last 8 years the compound annual growth rate for Jiangsu Kanion Pharmaceutical Co Ltd's revenue is 7%. The projected CAGR for the next 3 years is 17%.

What is Jiangsu Kanion Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
21%

For the last 8 years the compound annual growth rate for Jiangsu Kanion Pharmaceutical Co Ltd's operating income is 2%. The projected CAGR for the next 3 years is 21%.

What is Jiangsu Kanion Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Jiangsu Kanion Pharmaceutical Co Ltd's net income is 5%. The projected CAGR for the next 3 years is 20%.

ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.